[go: up one dir, main page]

CL2020000169A1 - Compuestos macrocíclicos y usos de los mismos. - Google Patents

Compuestos macrocíclicos y usos de los mismos.

Info

Publication number
CL2020000169A1
CL2020000169A1 CL2020000169A CL2020000169A CL2020000169A1 CL 2020000169 A1 CL2020000169 A1 CL 2020000169A1 CL 2020000169 A CL2020000169 A CL 2020000169A CL 2020000169 A CL2020000169 A CL 2020000169A CL 2020000169 A1 CL2020000169 A1 CL 2020000169A1
Authority
CL
Chile
Prior art keywords
compounds
macrocyclic compounds
csf1r
met
methods
Prior art date
Application number
CL2020000169A
Other languages
English (en)
Inventor
Dayong Zhai
Jingrong Jean Cui
Evan W Rogers
Jane Ung
Jeffrey Whitten
Wei Deng
Xin Zhang
Zhongdong Huang
Jing Liu
Han Zhang
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65039935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2020000169(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of CL2020000169A1 publication Critical patent/CL2020000169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)

Abstract

LA PRESENTE DESCRIPCIÓN SE REFIERE A CIERTOS COMPUESTOS MACROCÍCLICOS QUE INHIBEN SRC Y MET, Y/O CSF1R, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN TALES COMPUESTOS, Y MÉTODOS PARA USAR TALES COMPUESTOS PARA TRATAR EL CÁNCER.
CL2020000169A 2017-07-28 2020-01-20 Compuestos macrocíclicos y usos de los mismos. CL2020000169A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762538193P 2017-07-28 2017-07-28
US201862700990P 2018-07-20 2018-07-20

Publications (1)

Publication Number Publication Date
CL2020000169A1 true CL2020000169A1 (es) 2020-08-14

Family

ID=65039935

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000169A CL2020000169A1 (es) 2017-07-28 2020-01-20 Compuestos macrocíclicos y usos de los mismos.

Country Status (29)

Country Link
US (4) US11286264B2 (es)
EP (1) EP3658148B1 (es)
JP (2) JP7224334B2 (es)
KR (1) KR102645316B1 (es)
CN (1) CN111182903A (es)
AU (1) AU2018306328B2 (es)
BR (1) BR112020001695A2 (es)
CA (1) CA3069232A1 (es)
CL (1) CL2020000169A1 (es)
CO (1) CO2020000633A2 (es)
DK (1) DK3658148T3 (es)
ES (1) ES2986593T3 (es)
FI (1) FI3658148T3 (es)
HR (1) HRP20241197T1 (es)
IL (1) IL271964B2 (es)
LT (1) LT3658148T (es)
MY (1) MY201925A (es)
PE (1) PE20200700A1 (es)
PH (1) PH12020500033A1 (es)
PL (1) PL3658148T3 (es)
PT (1) PT3658148T (es)
RS (1) RS65884B1 (es)
SA (1) SA520411108B1 (es)
SG (1) SG11202000356VA (es)
SI (1) SI3658148T1 (es)
SM (1) SMT202400343T1 (es)
TW (1) TWI818917B (es)
UA (1) UA126158C2 (es)
WO (1) WO2019023417A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3572416T (lt) 2014-01-24 2022-12-27 Turning Point Therapeutics, Inc. Diarilo makrociklai, kaip baltymų kinazių moduliatoriai
JP6871903B2 (ja) 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY201925A (en) * 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
CN109516999B (zh) * 2017-11-01 2021-08-17 郑州泰基鸿诺医药股份有限公司 用作蛋白质激酶调节剂的化合物及其应用
PL3728271T3 (pl) 2017-12-19 2023-01-23 Turning Point Therapeutics, Inc. Związki makrocykliczne do leczenia chorób
PL3786167T3 (pl) 2018-04-25 2024-11-25 Primegene (Beijing) Co., Ltd. Diarylowy związek makrocykliczny i kompozycja farmaceutyczna oraz ich zastosowanie
FI3870579T3 (fi) 2018-10-22 2025-01-02 Alumis Inc Tyk2-inhibiittoreita ja niiden käyttöjä
CN113811534B (zh) * 2019-03-11 2024-10-29 阿鲁米斯公司 Tyk2抑制剂和其用途
EP3974434B1 (en) 2019-05-21 2025-11-19 Zhejiang Hisun Pharmaceutical Co., Ltd. Macrolide derivatives, preparation method and application thereof
CN114423762B (zh) * 2019-09-30 2024-03-29 浙江海正药业股份有限公司 大环类衍生物及其制备方法和用途
WO2021178296A1 (en) * 2020-03-02 2021-09-10 Turning Point Therapeutics, Inc. Therapeutic uses of macrocyclic compounds
CN113754682B (zh) * 2020-06-04 2023-01-06 赛诺哈勃药业（成都）有限公司 具有大环结构的化合物及其用途
CN111620881B (zh) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 拉罗替尼衍生物及其制备方法和应用
CN116635076A (zh) * 2020-12-17 2023-08-22 荣山医药股份有限公司 大环化合物及其用途
CN114685532A (zh) * 2020-12-31 2022-07-01 正大天晴药业集团股份有限公司 大环类化合物及其医药用途
CN116829562B (zh) * 2021-02-10 2025-04-01 深圳国顺康医药科技有限公司 一种巨环化合物、药物组合物以及其用途
UY39779A (es) * 2021-05-21 2023-01-31 Blossomhill Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
WO2023078267A1 (zh) * 2021-11-02 2023-05-11 赛诺哈勃药业（成都）有限公司 作为蛋白激酶调节剂的含氨基大环化合物
EP4433462A4 (en) * 2021-11-16 2025-07-16 Prodeg Llc USP9X INHIBITORS
US12168640B2 (en) 2021-11-16 2024-12-17 ProDeg, LLC USP9X inhibitors
IL313670A (en) 2021-12-30 2024-08-01 Biomea Fusion Inc Pyrazine compounds as inhibitors of FLT3

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT690843E (pt) 1993-03-25 2001-01-31 Upjohn Co Derivados de indolo substituidos com formilo ou ciano possuindo actividade dopaminergica
PT657458E (pt) 1993-12-07 2002-02-28 Lilly Co Eli Inibidores de proteina cinase c
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
WO2002016369A2 (en) 2000-08-25 2002-02-28 Sloan-Kettering Institute For Cancer Research Novel macrocycles and uses thereof
CA2431187A1 (en) 2000-12-08 2002-06-13 Ortho-Mcneil Pharmaceutical, Inc. Macroheterocylic compounds useful as kinase inhibitors
MX2011002470A (es) 2008-09-08 2011-04-05 Merck Patent Gmbh Pirimidinas macrociclicas como inhibidores de aurora cinasa.
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. ＴＲＫ 키나아제 억제제로서 치환된 피라졸로［１,５­ａ］ 피리미딘 화합물
PE20110828A1 (es) 2008-10-31 2011-11-22 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak
NZ598766A (en) 2009-10-13 2013-09-27 Elanco Animal Health Ireland Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
CN102933765B (zh) 2011-06-10 2014-03-26 曼泰克株式会社 污染防止剂组合物
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
EP2744507A4 (en) 2011-08-19 2015-01-28 Merck Sharp & Dohme CRYSTAL FORMS OF AN HCV PROTEASE HEMMER
EA025881B1 (ru) 2011-09-30 2017-02-28 Онкодизайн С.А. Макроциклические ингибиторы flt3-киназы
NZ627900A (en) 2012-03-06 2016-08-26 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN104470523B (zh) 2012-03-09 2017-07-11 莱西肯医药有限公司 基于咪唑并[1,2‑b]哒嗪的化合物、包含它们的组合物及其使用方法
DK2834243T3 (en) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pyrazole [1,5-a] pyrimidine-based compounds, compositions comprising them and methods for their use
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
LT3572416T (lt) * 2014-01-24 2022-12-27 Turning Point Therapeutics, Inc. Diarilo makrociklai, kaip baltymų kinazių moduliatoriai
TWI736134B (zh) * 2014-09-11 2021-08-11 美商特普醫葯公司 作為蛋白質激酶之調節劑的二芳基巨環
JP6871903B2 (ja) * 2015-07-02 2021-05-19 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． プロテインキナーゼのモジュレーターとしてのキラルジアリール大環状分子
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
US20180325901A1 (en) 2015-07-21 2018-11-15 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
LT3371190T (lt) * 2015-11-06 2022-08-10 Incyte Corporation Heterocikliniai junginiai, kaip pi3k-gama inhibitoriai
RU2019105587A (ru) * 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
US10829492B2 (en) * 2016-10-28 2020-11-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Amino pyrazolopyrimidine compound used as neurotrophic factor tyrosine kinase receptor inhibitor
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
MY201925A (en) 2017-07-28 2024-03-23 Turning Point Therapeutics Inc Macrocyclic compounds and uses thereof
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
EP3783000B1 (en) 2018-04-18 2022-07-06 Hitgen Inc. Macrocyclic kinase inhibitor

Also Published As

Publication number Publication date
US20210214373A1 (en) 2021-07-15
JP7554300B2 (ja) 2024-09-19
PE20200700A1 (es) 2020-06-23
CA3069232A1 (en) 2019-01-31
JP2023065403A (ja) 2023-05-12
DK3658148T3 (da) 2024-10-07
JP2020528907A (ja) 2020-10-01
TW201920198A (zh) 2019-06-01
TWI818917B (zh) 2023-10-21
AU2018306328B2 (en) 2023-03-09
RS65884B1 (sr) 2024-09-30
AU2018306328A1 (en) 2020-01-16
PH12020500033A1 (en) 2020-09-28
US20200157119A1 (en) 2020-05-21
WO2019023417A1 (en) 2019-01-31
FI3658148T3 (fi) 2024-09-20
UA126158C2 (uk) 2022-08-25
US11155563B2 (en) 2021-10-26
LT3658148T (lt) 2024-09-10
US11981684B2 (en) 2024-05-14
EP3658148B1 (en) 2024-07-10
US20220324879A1 (en) 2022-10-13
MY201925A (en) 2024-03-23
SI3658148T1 (sl) 2024-10-30
HRP20241197T1 (hr) 2024-11-22
US11286264B2 (en) 2022-03-29
IL271964A (en) 2020-02-27
EP3658148A1 (en) 2020-06-03
US20240391935A1 (en) 2024-11-28
PT3658148T (pt) 2024-08-26
KR102645316B1 (ko) 2024-03-07
IL271964B1 (en) 2024-08-01
EP3658148A4 (en) 2021-04-28
CN111182903A (zh) 2020-05-19
JP7224334B2 (ja) 2023-02-17
KR20200034998A (ko) 2020-04-01
ES2986593T3 (es) 2024-11-12
CO2020000633A2 (es) 2020-01-31
IL271964B2 (en) 2024-12-01
SA520411108B1 (ar) 2024-03-03
SG11202000356VA (en) 2020-02-27
BR112020001695A2 (pt) 2020-07-21
SMT202400343T1 (it) 2024-11-15
PL3658148T3 (pl) 2024-10-07

Similar Documents

Publication Publication Date Title
CL2020000169A1 (es) Compuestos macrocíclicos y usos de los mismos.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2019000820A1 (es) Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134)
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CO2019007839A2 (es) Composiciones y métodos para inhibir la acción de la arginasa
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
MX2020001360A (es) Macrociclos de diarilo como moduladores de la proteina quinasa.
CU20160162A7 (es) Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen
CL2017001046A1 (es) Inhibidoes del bromodominio
CO2017001994A2 (es) Compuestos activos hacia bromodominios
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2018005528A (es) Inhibidores de ret.
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MX2016002137A (es) Ciertas entidades quimicas, composiciones y metodos.
CR20150316A (es) Compuestos y sus métodos de empleo
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
GT201500190A (es) Lactamas fusionadas de arilo y heteroarilo
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2021006734A (es) Metodo para tratar el cancer.
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2019000946A (es) Administracion y dosificacion de diaminofenotiazinas.